The recent advancements in sequencing technologies may overcome the cross-laboratory discrepancies in mRNA measurement, and targeted sequencing of uPA and PAI-1 mRNA may provide concrete evidence as to whether they can be used as biomarkers for cancer patients. Here, PLAU is linked to cancer.